Drugs / IGM-6268
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05184218 | Jan → May 2022 | COVID-19 | IGM Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05160402 | Dec 2021 → Jun 2022 | — | IGM Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGM-6268 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05160402 ↗ |
| Action | Inhibit | “The primary mechanism of action of IGM-6268 is to block the binding of the SARS-CoV-2 RBD on the spike protein to human angiotensin converting enzyme 2 (hACE2), the cellular...” NCT05160402 ↗ |
| Route | Intranasal | “IGM-6268 administered intranasally and intraorally in healthy volunteers” NCT05160402 ↗ |